Anxiety associated with comorbid depressionMÖLLER, Hans-Jürgen.The Journal of clinical psychiatry. Supplement. 2002, Vol 63, Num 14, pp 22-26, 5 p.Article

Clinical evaluation of negative symptoms in schizophreniaMÖLLER, Hans-Jürgen.European psychiatry. 2007, Vol 22, Num 6, pp 380-386, issn 0924-9338, 7 p.Article

Development of DSM-V and ICD-11: Tendencies and potential of new classifications in psychiatry at the current state of knowledgeMÖLLER, Hans-Jürgen.Psychiatry and clinical neurosciences (Carlton. Print). 2009, Vol 63, Num 5, pp 595-612, issn 1323-1316, 18 p.Article

Long-acting risperidone : Focus on safetyMÖLLER, Hans-Jürgen.Clinical therapeutics. 2006, Vol 28, Num 5, pp 633-651, issn 0149-2918, 19 p.Article

Management of the negative symptoms of schizophrenia: New treatment optionsMÖLLER, Hans-Jürgen.CNS drugs. 2003, Vol 17, Num 11, pp 793-823, issn 1172-7047, 31 p.Article

Long-acting injectable risperidone for the treatment of schizophrenia : Clinical perspectivesMOLLER, Hans-Jürgen.Drugs (Basel). 2007, Vol 67, Num 11, pp 1541-1566, issn 0012-6667, 26 p.Article

Repetitive transcranial magnetic stimulation: Does it have potential in the treatment of depression?PADBERG, Frank; MÖLLER, Hans-Jürgen.CNS drugs. 2003, Vol 17, Num 6, pp 383-403, issn 1172-7047, 21 p.Article

Reception of Kraepelin's ideas 1900―1960PALM, Ulrich; MÖLLER, Hans-Jürgen.Psychiatry and clinical neurosciences (Carlton. Print). 2011, Vol 65, Num 4, pp 318-325, issn 1323-1316, 8 p.Article

Anxiety: new treatment perspectivesRICKELS, Karl; MÖLLER, Hans-Jürgen.The Journal of clinical psychiatry. Supplement. 2002, Vol 63, Num 14, 35 p.Serial Issue

Design of clinical trials of antidepressants: Should a placebo control arm be included?FRITZE, Jürgen; MÖLLER, Hans-Jürgen.CNS drugs. 2001, Vol 15, Num 10, pp 755-764, issn 1172-7047Article

The role of extended-release benzodiazepines in the treatment of anxiety: A risk-benefit evaluation with a focus on extended-release alprazolamKLEIN, Ehud.The Journal of clinical psychiatry. Supplement. 2002, Vol 63, Num 14, pp 27-33, 7 p.Article

Amisulpride: limbic specificity and the mechanism of antipsychotic atypicalityMÖLLER, Hans-Jürgen.Progress in neuro-psychopharmacology & biological psychiatry. 2003, Vol 27, Num 7, pp 1101-1111, issn 0278-5846, 11 p.Article

The management of panic disorderSHEEHAN, David V.The Journal of clinical psychiatry. Supplement. 2002, Vol 63, Num 14, pp 17-21, 5 p.Article

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?MONTGOMERY, Stuart A; MÖLLER, Hans-Jürgen.International clinical psychopharmacology. 2009, Vol 24, Num 3, pp 111-118, issn 0268-1315, 8 p.Article

Electroconvulsive therapy and its different indicationsBAGHAI, Thomas C; MÖLLER, Hans-Jürgen.Dialogues in clinical neuroscience. 2008, Vol 10, Num 1, pp 105-117, issn 1294-8322, 13 p.Article

Recent progress in pharmacological and non-pharmacological treatment options of major depressionBAGHAI, Thomas C; MÖLLER, Hans-Jürgen; RUPPRECHT, Rainer et al.Current pharmaceutical design. 2006, Vol 12, Num 4, pp 503-515, issn 1381-6128, 13 p.Article

Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophreniaMAURER, Iris; ZIERZ, Stephan; MÖLLER, Hans-Jürgen et al.Schizophrenia research. 2001, Vol 48, Num 1, pp 125-136, issn 0920-9964Article

Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issueFOUNTOULAKIS, Konstantinos N; MÖLLER, Hans-Jürgen.Journal of psychopharmacology (Oxford). 2012, Vol 26, Num 5, pp 744-750, issn 0269-8811, 7 p.Article

Effectiveness studies: advantages and disadvantagesMÖLLER, Hans-Jürgen.Dialogues in clinical neuroscience. 2011, Vol 13, Num 2, pp 199-207, issn 1294-8322, 9 p.Article

Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admissionBOTTLENDER, Ronald; STRAUSS, Anton; MÖLLER, Hans-Jürgen et al.Schizophrenia research. 2010, Vol 116, Num 1, pp 9-15, issn 0920-9964, 7 p.Article

The epidemiology of anxiety disorders: Prevalence and societal costsLEPINE, Jean-Pierre.The Journal of clinical psychiatry. Supplement. 2002, Vol 63, Num 14, pp 4-8, 5 p.Article

Bipolar disorder and schizophrenia: Distinct illnesses or a continuum?MOLLER, Hans-Jürgen.The Journal of clinical psychiatry. Supplement. 2003, Vol 64, Num 6, pp 23-27, 5 p.Conference Paper

State of the Art: Treatment of Bipolar Disorders : BIPOLAR DISORDERSEVERUS, Emanuel; SCHAAFF, Nadine; MÖLLER, Hans-Jurgen et al.CNS neuroscience & therapeutics (Print). 2012, Vol 18, Num 3, pp 214-218, issn 1755-5930, 5 p.Article

Effects of different antidepressant treatments on the core of depressionBAGHAI, Thomas C; ESER, Daniela; MOLLER, Hans-Jürgen et al.Dialogues in clinical neuroscience. 2008, Vol 10, Num 3, pp 309-320, issn 1294-8322, 12 p.Article

Fifteen-year follow-up of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorders : the prognostic significance of psychotic featuresJÄGER, Markus; BOTTLENDER, Ronald; STRAUSS, Anton et al.Comprehensive psychiatry. 2005, Vol 46, Num 5, pp 322-327, issn 0010-440X, 6 p.Article